8-K: Aethlon Medical Reports Q3 2026 Results, Advances Clinical Programs

Aethlon Medical, Inc. announced its fiscal third quarter 2026 financial results, highlighting continued clinical and research program advancements alongside year-to-date cost efficiencies.

Summary

• Reported financial results for the fiscal third quarter ended December 31, 2025.
• Maintained compliance with Nasdaq listing requirements.
• Cohort 2 of the Australian oncology trial is actively progressing.
• Advanced preclinical extracellular vesicle (EV) research platform, including Long COVID data published on bioRxiv and submitted for peer review.
• Continued evaluation of Hemopurifier (HP) compatibility with Stavro's SLAMB system for simplified blood treatment.
• Achieved year-to-date operating expense decline of 26.9% compared to the prior year, reflecting disciplined cost controls.
• Cash balance was approximately $7.0 million as of December 31, 2025.
• Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% from $1.81 million in the same period in 2024.
• Operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period.
• Net loss for the three months ended December 31, 2025, was $(2.018) million, compared to $(1.754) million in the prior-year period.
• Basic and diluted loss per share for the three months ended December 31, 2025, was $(2.45), compared to $(10.05) in the prior-year period.
• Consolidated operating expenses for the nine months ended December 31, 2025, were approximately $5.36 million, a decrease of $1.98 million or 26.9% from $7.34 million in the same period in 2024.
• Net loss for the nine months ended December 31, 2025, was $(5.267) million, compared to $(7.133) million in the same period in 2024.
• Basic and diluted loss per share for the nine months ended December 31, 2025, was $(11.01), compared to $(48.35) in the same period in 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative update. While clinical and research progress is positive and year-to-date cost controls are commendable, the increase in quarterly operating expenses and net loss, coupled with the explicit risk of needing additional financing within 12 months, introduces financial uncertainty.

Positives

• Maintained Nasdaq listing compliance, with all prior compliance matters resolved.
• Cohort 2 of the Australian oncology trial is actively progressing, building on Cohort 1's favorable directional improvements in extracellular vesicle and immune cell numbers, as well as safety and tolerability.
• Preclinical Long COVID research demonstrated that the GNA affinity resin binds EVs from Long COVID patient samples and reduces microRNAs associated with immune dysregulation; these findings were published on bioRxiv and submitted for peer review.
• Evaluating Hemopurifier compatibility with Stavro's SLAMB system, a simplified blood treatment platform, which may support future use in oncology units and infusion centers without requiring large dialysis equipment or a supervising nephrologist.
• Consolidated operating expenses declined 26.9% ($1.98 million) during the nine months ended December 31, 2025, compared to the prior year, reflecting disciplined cost controls.
• Cash balance increased to approximately $7.0 million as of December 31, 2025, from $5.5 million at March 31, 2025.
• The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for the treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy, and for the treatment of life-threatening viruses not addressed with approved therapies.

Negatives

• Consolidated operating expenses for the three months ended December 31, 2025, increased by $250,000 (13.6%) to $2.06 million compared to $1.81 million in the same period in 2024.
• Operating loss for the three months ended December 31, 2025, increased to $2.06 million compared to $1.81 million in the prior year period.
• Net loss for the three months ended December 31, 2025, increased to $(2.018) million compared to $(1.754) million in the prior-year period.
• Interest income, net, decreased to $43,871 for the three months ended December 31, 2025, from $59,964 in the prior-year period.

Risks

• The investigational status and potential safety, feasibility, or utility of the Hemopurifier.
• The company's ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia.
• The timing, scope, design, and potential outcomes or interpretation of such studies.
• The company's ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use.
• The availability and adequacy of capital to support ongoing operations.
• The company's ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles.
• Cash on hand may not be sufficient to support operations for the next 12 months without additional financing.
• The company's ability to raise additional capital on terms favorable to the company, or at all.
• The company's ability to successfully complete development of the Hemopurifier.
• The company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting.
• The company's ability to achieve and realize the anticipated benefits from operational and financial milestones.
• The company's ability to maintain its Nasdaq listing.
• The company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the company.
• The company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the company.
• The company's ability to manage and successfully complete its clinical trials.
• The company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials.
• Unforeseen changes in regulatory requirements.
• The company's collaborative research with UCSF Long Covid Clinic.
• The company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks.

Future Outlook

The company remains committed to advancing its clinical programs and research initiatives with operational discipline, aiming to deliver therapeutic solutions for cancer and life-threatening infectious diseases. Management believes recent progress in trials, research collaborations, and technology development moves them closer to this goal. They also plan to extend research by investigating the removal of platelet-derived EVs and microRNAs by the Hemopurifier in plasma from patients with select indications, reflecting the Hemopurifier's potential as a 'pipeline within a single device'.

Management Comments

• "We remain committed to advancing our clinical programs and research initiatives with operational discipline."
• "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."

Industry Context

StockSavvy.ai notes that Aethlon Medical operates in the highly competitive and capital-intensive medical therapeutics sector, specifically targeting oncology and infectious diseases with its Hemopurifier device. The focus on extracellular vesicles (EVs) and conditions like Long COVID positions it in an emerging area of research, while its collaboration with Stavro for a simplified blood treatment system addresses a practical need for broader clinical application, potentially differentiating it from traditional dialysis-dependent systems. The Breakthrough Device Designation indicates regulatory recognition of its potential impact.

Comparison to Industry Standards

• The Hemopurifier's Breakthrough Device Designation for advanced/metastatic cancer and life-threatening viruses positions it among a select group of innovative medical devices recognized by the FDA for their potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.
• The company's focus on extracellular vesicles (EVs) for cancer and infectious diseases, including Long COVID, aligns with broader industry trends exploring novel therapeutic targets beyond traditional drug mechanisms. For example, companies like Codiak BioSciences (though now bankrupt) and Evox Therapeutics have explored EV-based therapeutics, highlighting the innovative but challenging nature of this field.
• The reported year-to-date operating expense reduction of 26.9% demonstrates a focus on cost efficiency, which is crucial for clinical-stage biotech companies that typically incur significant R&D expenses without immediate revenue. This contrasts with larger, revenue-generating pharmaceutical companies that have established pipelines and broader operational budgets.
• The ongoing Australian oncology trial with Keytruda or Opdivo (anti-PD-1 agents) places Aethlon in the competitive immuno-oncology space, where many companies are exploring combination therapies to improve patient outcomes. Success in such trials could differentiate the Hemopurifier as an adjunct therapy.

Stakeholder Impact

• Shareholders face potential for long-term value creation if clinical trials succeed, but also dilution risk due to potential future capital raises and ongoing losses. The significant increase in weighted average shares outstanding indicates past dilution.
• Patients may benefit from continued progress in clinical trials, offering hope for new therapeutic solutions for cancer and life-threatening infectious diseases.
• Employees may experience stability in current roles due to continued operational discipline and program advancement, but financial constraints could impact future growth.
• Creditors might view the need for future financing and ongoing losses as a concern, although the current cash balance provides some short-term buffer.

Next Steps

• Continue enrollment and treatment of participants in Cohort 2 of the Australian oncology trial.
• Continue evaluation of Hemopurifier compatibility with Stavro's SLAMB system.
• Await peer review of Long COVID data submitted to a journal.
• Explore other cargo in EVs that may be removed by the Hemopurifier.
• Extend work by investigating the removal of platelet-derived EVs and microRNAs by the Hemopurifier in plasma from patients with select indications.
• Host a conference call on February 12, 2026, at 4:30 p.m. ET to review results and corporate developments.

Key Dates

Recommendation

Aethlon Medical shows promising clinical and scientific advancements with its Hemopurifier, particularly in oncology and Long COVID research, supported by year-to-date cost efficiencies. However, the increase in quarterly operating expenses and net loss, coupled with the explicit disclosure of needing additional capital within the next 12 months, introduces significant financial risk. While the technology has breakthrough potential, the current financial trajectory and the inherent risks of clinical development warrant a cautious "hold" recommendation. Investors should monitor future financing activities and clinical trial milestones closely.

Keywords

Aethlon Medical, AEMD, Hemopurifier, oncology, cancer treatment, infectious diseases, extracellular vesicles, EVs, Long COVID, clinical trials, medical device, biotechnology, Nasdaq, financial results, Q3 2026, biotech, medical therapeutics